Long-Term complications of adjuvant chemotherapy for early stage breast cancer

Breast Disease

Volumn 21, Issue , 2004, Pages 55-64

  Partridge, Ann H ^a   Winer, Eric P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

AMENORRHEA; BODY WEIGHT DISORDER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; EARLY CANCER; EARLY MENOPAUSE; FATIGUE; FEMALE; FEMALE SEXUAL DYSFUNCTION; HEART DISEASE; HUMAN; INCIDENCE; LEUKEMIA; MEDICAL DECISION MAKING; MYELODYSPLASTIC SYNDROME; NEUROPATHY; OSTEOPOROSIS; OVARY INSUFFICIENCY; PARESTHESIA; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SENSORIMOTOR NEUROPATHY; SYMPTOM; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 12444318710     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-2004-21108     Document Type: Review

References (84)

1. Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group,Lancet 352 (1998), 930-942.
2. M.L. Meistrich, R. Vassilopoulou-Sellin and L.I. Lipshultz, Gonadal Dysfunction, in: Cancer Priciples and Practice of Oncology, V.T. DeVita, S. Hellman and S.A. Rosenberg, eds, 6th ed. Philadelphia: Lippincott Williams and Wilkins, 2001, pp.2923-2939.
3. H.J. Burstein and E.P. Winer, Reproductive Issues, in: Diseases of the Breast, 2nd ed., J.R. Harris, ed., Philadelphia: Lippincott Williams&Wilkins, 2000, pp. 1051-1059.
4. G.N. Hortobagyi, A.U. Buzdar, C.E. Marcus and T.L. Smith, Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute, NCI Monogr 1 (1986), 105-109.
5. P. Valagussa, D. De Candis, G. Antonelli and G. Bonadonna, VIII. Women's health perception and breast cancer: Issues of fertility, hormone substitution, and cancer prevention,Recent Results Cancer Res 140 (1996), 277-283.
6. B. Weber and E. Luporsi, Ovarian toxicity of breast cancer chemotherapy,Eur J Cancer 34(5) (1998), S42abstract 170.
7. P.J. Goodwin, M. Ennis, K.I. Pritchard, M. Trudeau and N. Hood, Risk of menopause during the first year after breast cancer diagnosis,J Clin Oncol 17 (1999), 2365-2370.
8. E.R. Stone, R.S. Slack, A. Novielli, M. Ellis, S. Baidas, E. Gelmann et al., Rate of chemotherapy related amenorrhea (CRA) associated with adjuvant adriamycin and cytoxan (AC) and adriamycin and cytoxan followed by taxol (AC+T) in early stage breast cancer,Breast Cancer Res Treat (2000), 64,61, abstract 224.
9. J. Byrne, T.R. Fears, M.H. Gail, D. Pee, R.R. Connelly, D.F. Austin et al., Early menopause in long-term survivors ofcancer during adolescence,Am J Obstet Gynecol 166 (1992), 788-793.
10. O. Pagani, A. O'Neill, M. Castiglione, R.D. Gelber, A. Goldhirsch, C.M. Rudenstam et al., Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: Results of the International Breast Cancer Study Group (IBCSG) Trial VI, Eur J Cancer 34 (1998), 632-640.
11. P.A. Ganz, A. Coscarelli, C. Fred, B. Kahn, M.L. Polinsky and L. Petersen, Breast cancer survivors: Psychosocial concerns and quality of life,Breast Cancer Res Treat 38 (1996), 183-199.
12. P.A. Ganz, J.H. Rowland, K. Desmond, B.E. Meyerowitz; and G.E. Wyatt, Life after breast cancer: Understanding women's health-related quality of life and sexual functioning,J Clin Oncol 16 (1998), 501-514.
13. B.E. Meyerowitz, K.A. Desmond, J.H. Rowland, G.E. Wyatt and P.A. Ganz, Sexuality following breast cancer,J Sex Marital Ther 25 (1999), 237-250.
14. H.J. Burstein and E.P. Winer, Primary care for survivors of breast cancer,N Engl J Med 343 (2000), 1086-1094.
15. P.A. Ganz, Menopause and breast cancer: Symptoms, late effects, and their management,Semin Oncol 28 (2001), 274-283.
16. D.L. Barton, C. Loprinzi and B. Gostout, Current management of menopausal symptoms in cancer patients,Oncology (Huntingt) 16 (2002), 67-72, 4; discussion 5-6, 9-80.
17. F.D. Kreuser, D. Felsenberg, C. Behles, H. Seibt-Jung, M. Mielcarek, V. Diehl et al., Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease,Ann Oncol 3(4) (1992), 105-110.
18. RE Bruning, M.J. Pit, M. de Jong-Bakker, A. van den Ende, A. Hart and A. van Enk, Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer,Br J Cancer 61 (1990), 308-310.
19. K.H. Park and C.H. Song, Bone mineral density in premenopausal anovulatory women,J Obstet Gynaecol 21 (1995), 89-97.
20. S.J. Howell, G. Berger, J.E. Adams and S.M. Shalet, Bone mineral density in women with cytotoxic-induced ovarian failure, Clin Endocrinol (Oxj) 49 (1998), 397-402.
21. C.L. Shapiro, J. Manola and M. Leboff, Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer,J Clin Oncol 19 (2001), 3306-3311.
22. C.K. Osborne, Tamoxifen in the treatment ofbreast cancer,N Engl J Med 339 (1998),1609-1618.
23. B. Fisher, J.P. Costantino, D.L. Wickerham, C.K. Redmond, M. Kavanah, W.M. Cronin et al., Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study,J Natl Cancer Inst 90 (1998), 1371-1388.
24. W. Demark-Wahnefried, E.P. Winer and B.K. Rimer, Why women gain weight with adjuvant chemotherapy for breast cancer,J Clin Oncol 11 (1993), 1418-1429.
25. W. Demark-Wahnefried, B.K. Rimer and E.P. Winer, Weight gain in women diagnosed with breast cancer,J Am Diet Assoc 97 (1997), 519-526, 29; quiz 27-28.
26. P.J. Goodwin, M. Ennis, K.I. Pritchard, D. McCready, J. Koo, S. Sidlofsky et al., Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis,J Clin Oncol 17 (1999), 120-129.
27. A. Aslani, R.C. Smith, B.J. Allen, N. Pavlakis, J.A. Levi, Changes inbody composition during breast cancer chemotherapy with the CMF-regimen, Breast Cancer Res Treat 57 (1999), 285-290.
28. C.L. Kutynec, L. McCargar, S.I. Barr and T.G. Hislop, Energy balance in women with breast cancer during adjuvant treatment,J Am Diet Assoc 99 (1999), 1222-1227.
29. W. Demark-Wahnefried, V Hars, M.R. Conaway, K. Havlin, B.K. Rimer, G. McElveen et al., Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy,Am J Clin Nutr 65 (1997), 1495-1501.
30. W. Demark-Wahnefried, B.L. Peterson, E.P. Winer, L. Marks, N. Aziz, P.K. Marcom et al., Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy,J Clin Oncol 19 (2001), 2381-2389.
31. C.L. Cheney, J. Mahloch and P. Freeny, Computerized tomography assessment of women with weight changes associated with adjuvant treatment for breast cancer,Am J Clin Nutr 66 (1997), 141-146.
32. G. Del Rio, S. Zirom, L. Valeriani, R. Menozzi, M. Bondi and M. Bertolini et al., Weight gain in women with breast cancer treated with adjuvant cyclophosphomide, methotrexate and 5-fluorouracil. Analysis of resting energy expenditure and body composition,Breast Cancer Res Treat 73 (2002), 267-273.
33. W.L. Donegan, A.J. Hartz and A.A. Rimm, The association of body weight with recurrent cancer ofthe breast,Cancer 41 (1978), 1590-1594.
34. R.T. Chlebowski, J.M. Weiner, R. Reynolds, J. Luce, L. Bulcavage and J.R. Bateman, Long-term survival following relapse after 5-FU but not CNIF adjuvant breast cancer therapy, Breast Cancer Res Treat 7 (1986), 23-30.
35. J.K. Camoriano, C.L. Loprinzi, J.N. Ingle, T.M. Themeau, J.E. Krook and M.H. Veeder, Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer,J Clin Oncol 8 (1990), 1327-1334.
36. K. Faber-Langendoen, Weight gain in women receiving adjuvant chemotherapy for breast cancer,Jama 276 (1996), 855-856.
37. R.D. Gelber, A. Goldhirsch, C. Hurny, J. Bernhard and R.J. Simes, Quality oflife in clinical trials of adjuvant therapies, in: Consensus Development Conference on the Treatment of Early Stage Breast Cancer, Washington, DC, Government Printing Office, 1992.
38. J.A. Broeckel, P.B. Jacobsen, L. Balducci, J. Horton and G.H. Lyman, Quality of life after adjuvant chemotherapy for breast cancer,Breast Cancer Res Treat 62 (2000), 141-150.
39. P.A. Ganz, K.A. Desmond, B. Leedham, J.H. Rowland, B.E. Meyerowitz and T.R. Belin, Quality of life in long-term, disease-free survivors of breast cancer: A follow-up study,J Nod Cancer Inst 94 (2002), 39-49.
40. J.E. Bower, P.A. Ganz, K.A. Desmond, J.H. Rowland, B.E. Meyerowitz and T.R. Belin, Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life,J Clin Oncol 18 (2000), 743-753.
41. K.H. Dow, B.R. Ferrell, S. Leigh, J. Ly and P. Gulasekaram, An evaluation ofthe quality of life among long-term survivors of breast cancer,Breast Cancer Res Treat 39 (1996), 261-273.
42. C. Lindley, S. Vasa, W.T. Sawyer and E.P. Winer, Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer,J Clin Oncol 16 (1998), 1380-1387.
43. P.B. Jacobsen and K. Stein, Is Fatigue a Long-term Side Effect of Breast Cancer Treatment? Cancer Control 6 (1999), 256-263.
44. M.A. Andrykowski, S.L. Curran and R. Lightner, Off-treatment fatigue in breast cancer survivors: A controlled comparison, J Behav Med 21 (1998), 1-18.
45. J.A. Broeckel, P.B. Jacobsen, J. Horton, L. Balducci and G.H. Lyman, Characteristics and correlates offatigue after adjuvant chemotherapy forbreast cancer,J Clin Oncol 16 (1998), 1689-1696.
46. P.A. Ganz, J.H. Rowland, K. Desmond, B.E. Meyerowitz and G.E. Wyatt, Life after breast cancer: Understanding women's health-related quality of life and sexual functioning,J Clin Oncol 16 (1998), 501-514.
47. C.L. Thors, J.A. Broeckel and P.B. Jacobsen, Sexual functioning in breast cancer survivors,Cancer Control 18 (2001), 442-448.
48. J.A. Broeckel, C.L. Thors, P.B. Jacobsen, M. Small and C.E. Cox, Sexual functioning in long-term breast cancer survivors treated with adjuvant chemotherapy,Breast Cancer Res Treat 75 (2002), 241-248.
49. P.A. Ganz, G.A. Greendale, L. Petersen, L. Zibecchi, B. Kahn and T.R. Belin, Managing menopausal symptoms in breast cancer survivors: Results of a randomized controlled trial,J Nod Cancer Inst 92 (2000), 1054-1064.
50. F.S. van Dam, S.B. Schagen, M.J. Muller, W. Boogerd, E. vd Wall, M.E. Droogleever Fortuyn et al., Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy, J Natl Cancer Inst 90 (1998), 210-218.
51. S.B. Schagen, F.S. van Dam, M.J. Muller, W. Boogerd, J. Lindeboom and P.F. Bruning, Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma,Cancer 85 (1999), 640-650.
52. C.B. Brezden, K.A. Phillips, M. Abdolell, T. Bunston and I.E. Tannock, Cognitive function in breast cancer patients receiving adjuvant chemotherapy,J Clin Oncol 18 (2000), 2695-2701.
53. P.A. Ganz, Cognitive dysfunction following adjuvant treatment of breast cancer: A new dose-limiting toxic effect? J Natl Cancer Inst 90 (1998), 182-183.
54. T.A. Ahles, A.J. Saykin, C.T. Furstenberg, B. Cole, L.A. Mott, K. Skalla et al., Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma,J Clin Oncol 20 (2002), 485-493.
55. J.A. O'Shaughnessy, Effects ofepoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy,Clin Breast Cancer 3(3) (2002), S116-120.
56. D. Barton and C. Loprinzi, Novel approaches to preventing chemotherapy-induced cognitive dysfunction in breast cancer: The art ofthe possible,Clin Breast Cancer 3(3) (2002), S121-127.
57. C.L. Shapiro and A. Recht, Side effects of adjuvant treatment of breast cancer,N Engl J Med 344 (2001), 1997-2008.
58. R.J. Freilich, C. Balmaceda, A.D. Seidman, M. Rubin and L.M. DeAngelis, Motor neuropathy due to docetaxel and paclitaxel, Neurology 47 (1996), 115-118.
59. P.H. Hilkens, J. Verweij, C.J. Vecht, G. Stoter and M.J. van den Bent, Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere),Ann Oncol 8 (1997), 187-190.
60. I.C. Henderson, D.A. Berry, G.D. Demetri, C.T. Cirrincione, L.J. Goldstein, S. Martino et al., Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer,J Clin Oncol 21 (2003), 1-9.
61. J. Nabholtz, T. Pienkowski, J. Mackey, M. Pawlicki, J. Guastalla, C. Vogel et al., Phase III trial comparing TAC (docetaxel, doxombicin, cyclophosphamide) with FAC (5-fluorouracil, doxombicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: Interim analysis of the BCIRG 001 study. [Abstract 141], Proc Am Soc Clin Oncol (2002), 21:36a.
62. M. Citron, D. Berry, C. Cirrincione, J. Carpenter, C. Hudis, W. Gradishar et al., Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741,J Clin Oncol 21(8) (15 April 2003), 1431-1439.
63. D.D. Von Hoff, M.W. Layard, P. Basa, H.L. Davis, A.L. Von Hoff, M. Rozencweig et al., Risk factors for doxorubicin-induced congestive heart failure,Ann Intern Med 91 (1979), 710-717.
64. P.K. Singal and N. Iliskovic, Doxombicin-induced cardiomy-opathy, N Engl J Med 339 (1998), 900-905.
65. P. Valagussa, M. Zambetti, S. Biasi, A. Molitemi, R. Zucali and G. Bonadonna, Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer, Ann Oncol 5 (1994), 209-216.
66. M. Zambetti, A. Molitemi, C. Materazzo, M. Stefanelli, S. Cipriani, P. Valagussa et al., Long-Term Cardiac Sequelae in Operable Breast Cancer Patients Given Adjuvant Chemotherapy With or Without Doxombicin and Breast Irradiation,J Chn Oncol 19 (2001), 37-43.
67. K. Albain, S. Green, P. Ravdin, E. Cobau, J. Levine, K. Ingle et al., Overall survival after cyclophosphamide, adriamycin, 5-FU, and tamoxifen (CAFT) is superior to T alone in post- menopausal, receptor (+), node (+) breast cancer: New findings from phase III Southwest Oncology Group Intergroup Trial S8814 (INT-0100),Proc Am Soc Chn Oncol (2001), 20:24a abstract 94.
68. C.L. Shapiro, P.H. Hardenbergh, R. Gelman, D. Blanks, P. Hauptman, A. Recht et al., Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients,J Clin Oncol 16 (1998), 3493-3501.
69. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2, N Engl J Med 344 (2001),783-792.
70. A. Seidman, C. Hudis, M.K. Pierri, S. Shak, V Paton, M. Ashby et al., Cardiac dysfunction in the trastuzurnab clinical trials experience,J Chn Oncol 20 (2002), 1215-1221.
71. D.L. Keefe, Trastuzurnab-associated cardiotoxicity,Cancer 95 (2002), 1592-1600.
72. G.W. Sledge, A. O'Neill, A.D. Thor, S.P. Kahanic, P.J. Zander, N.E. Davidson et al., Pilottrial ofpaclitaxel-herceptin adjuvant therapy for early stage breast cancer (E2198). [abstract],Br Cancer Res Treat (2001), 69:209 abstract 4.
73. H.J. Burstein, L.N. Harris, R. Gelman, S.C. Lester, R.A. Nunes, C.M. Kaelin et al., Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study,J Clin Oncol 21 (2003),46-53.
74. R.E. Curtis, J.D. Boice, M. Stovall, L. Bernstein, R.S. Greenberg, J.T. Flannery et al., Risk ofleukernia after chemotherapy and radiation treatment for breast cancer,N Engl J Med 326 (1992), 1745-1751.
75. E. Diamandidou, A.U. Buzdar, T.L. Smith, D. Frye, M. Witjaksono and G.N. Hortobagyi, Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas M.D. Anderson Cancer Center experience, J Clin Oncol 14 (1996), 2722-2730.
76. B. Fisher, S. Anderson, D.L. Wickerham, A. DeCillis, N. Dimitrov, E. Mamounas et al., Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen forthe treatment ofprimary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22,J Clin Oncol 15 (1997), 1858-1869.
77. M.N. Levine, V.H. Bramwell, K.I. Pritchard, B.D. Norris, L.E. Shepherd, H. Abu-Zahra et al., Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group [see comments],J Chn Oncol 16 (1998), 2651-2658.
78. G. Chaplain, C. Milan, C. Sgro, P.M. Carli and C. Bonithon-Kopp, Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: A population-based study,J Clin Oncol 18 (2000), 2836-2342.
79. J. Pedersen-Bjergaard, Acute promyelocytic leukemia with t(l5;17) following inhibition of DNA topoisomerase II,Ann Oncol 6 (1995), 751-753.
80. M.S. Tallman, R. Gray, J.M. Bennett, D. Variakojis, N. Robert, W.C. Wood et al., Leukemogenic potential ofadjuvant chemotherapy for early-stage breast cancer: The Eastern Cooperative Oncology Group experience,J Clin Oncol 13 (1995), 1557-1563.
81. M.J. Thirman and R.A. Larson, Therapy-related myeloid leukemia, Hematol Oncol Clin North Am 10 (1996),293-320.
82. B. Fisher, S. Anderson, A. DeCillis, N. Dimitrov, J.N. Atkins, L. Fehrenbacher et al., Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25,J Clin Oncol 17 (1999), 3374-3388.
83. P. Valagussa, A. Moliterni, M. Terenziani, M. Zambetti and G. Bonadonna, Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer,Ann Oncol 5 (1994), 803-838.
84. E.P. Mamounas, Evaluating the use of paclitaxel following doxorubicin/cyclophosphamide in patients with breast cancer and postive axillary nodes. Adjuvant Therapy for Breast Cancer- NIH Consensus Development Conferencem, Bethesda, MD: NIH; 2000.